Latest Avanir Pharmaceuticals Inc. Stories
Expedited Development Path will Allow Seamless Integration of AVP-786 into ongoing Clinical Programs ALISO VIEJO, Calif., June 5, 2013 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced that the U.S. Food and Drug Administration (FDA) has agreed to an expedited development pathway for their next-generation compound, AVP-786, requiring only a limited pre-clinical package as part of the Investigational New Drug (IND) application. Upon completion of these...
ALISO VIEJO, Calif., May 22, 2013 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced that company management will present an overview of the company at the following conferences. Deutsche Bank 38th Annual Health Care Conference Presentation date: Wednesday May 29, 2013 Presentation time: 12:00 p.m. P.T. Jefferies 2013 Global Healthcare Conference Presentation date: Wednesday June 5, 2013 Presentation time: 8:30 a.m. E.T. A live webcast and 30-day...
ALISO VIEJO, Calif., May 8, 2013 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today reported financial results for the three and six months ended March 31, 2013. (Logo: http://photos.prnewswire.com/prnh/20130207/LA55901LOGO) Quarterly Financial Highlights Total company net revenues of $17.4 million Gross and net NUEDEXTA® sales increased to $20.8 million and $16.5 million, respectively, representing growth of 14% and 11% versus the previous quarter Cash, cash...
ALISO VIEJO, Calif., May 1, 2013 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) will report financial results for the quarter ended March 31, 2013 after market close on Wednesday May 8, 2013. The company will conduct a conference call and an audio webcast at 1:30 pm Pacific Time (4:30 pm Eastern Time) on the same day. Conference Call Information:Domestic callers: 1 (877) 703 6106International callers: +1 (857) 244-7305Passcode: 62763985 Webcast information: Visit...
NUEDEXTA recommended for the treatment of PBA, irrespective of neurologic cause ALISO VIEJO, Calif., April 26, 2013 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for NUEDEXTA(®) (dextromethorphan hydrobromide and quinidine sulfate), recommending NUEDEXTA be approved for the treatment of pseudobulbar affect (PBA),...
LONDON, April 10, 2013 /PRNewswire/ -- One of the major trends to emerge in the healthcare industry in the last year has been the expiration of patents on several blockbuster drugs. This had led to increasing competition from generic drug companies such as Actavis Inc. (NYSE: ACT) and Avanir Pharmaceuticals Inc. (NASDAQ: AVNR). For major drug manufacturers such as Zogenix Inc. (NASDAQ: ZGNX), the key will be to continue to boost their product pipeline. Major drug manufacturers...
ALISO VIEJO, Calif., March 11, 2013 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced the appointment of Ms. Corinne Nevinny to the company's board of directors. Ms. Nevinny, a seasoned life sciences executive joins Avanir's board with broad healthcare industry experience across multiple disciplines. (Logo: http://photos.prnewswire.com/prnh/20130207/LA55901LOGO) Ms. Nevinny is General Partner of LMNVC LLC, a privately held early stage venture firm, which...
LONDON, March 8, 2013 /PRNewswire/ -- The U.S. Supreme Court last year upheld President Obama's Affordable Care Act (ACA). The ACA is the biggest overhaul of the healthcare industry in decades. While critics say that ACA will have a negative impact on the healthcare industry, supporters of the reform believe that the increase in the amount of insured individuals will ultimately benefit the industry. Apart from ACA, another major trend that is having an impact on drug makers...
Veterans with TBI at Risk for Debilitating Condition, Pseudobulbar Affect, Causing Uncontrollable Crying and/or Laughing Outbursts ALISO VIEJO, Calif., March 6, 2013 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) in collaboration with the Department of Veterans Affairs (VA) and United BioSource Corporation (UBC) today announced a pilot study to screen for pseudobulbar affect (PBA) symptoms in approximately 1,000 veterans with traumatic brain injury (TBI) . According to...
ALISO VIEJO, Calif., March 1, 2013 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced that company management will present an overview of the company at the following conferences in March. (Logo: http://photos.prnewswire.com/prnh/20130207/LA55901LOGO) Cowen & Company 33(rd) Annual Healthcare Conference Location: Boston Marriott Copley Place, Boston, MA Presentation date: Tuesday March 5, 2013 Presentation time: 9:20 a.m. E.T. 25(th) Annual ROTH...
